 |
 |
Ron Reiner, Thanks for forwarding the PR Newswire Release on Ropinirole. As a subject in the clinical trials I can attest to the benefits of the new drug (not yet available commercially) - Ropinirole - and I read the release with great interest. In your introductory remark you wrote "...Must be the Permax." NOT SO!! While both Ropinirole and PERMAX are dopmine agonists, they are very different drugs: A. PERMAX is an ergot derivative, hence the potential problems with a variety of side effects. Ropinirole is sythetic (I believe). B. Ropinirole works of the D2 dopamine receptors while PERMAX on the D1. My lay opinion, based only on personal experience (not a statistically valid sample) indicates that Ropinirole is an excellent drug for young onset PD, I sure hope the FDA moves quickly to examine the drug and approve it for use on young-onset PD patients. Anyone on PARKINSN know of FDA progress on Ropinirole approval? Ilan Levi [log in to unmask]